Melanoma vaccine - Argonex
Latest Information Update: 17 Nov 2006
At a glance
- Originator Argonex
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 17 Nov 2006 Discontinued - Phase-II for Malignant melanoma in USA (Injection)
- 23 Mar 2000 New profile